Qure.ai

Bottom line

Qure.ai is a suite of AI-powered radiology tools, primarily qXR for chest X-rays and qER for head CT analysis, deployed across 90-plus countries with particular strength in tuberculosis screening and triage workflows. The company, based in India, has built significant traction in resource-constrained settings where radiologist shortages make AI triage clinically necessary. However, US adoption appears limited, pricing transparency is nonexistent for most buyers, and the evidence base, while growing, remains thin compared to competitors with deeper US market penetration.

For hospital systems in low- and middle-income countries running TB programs or managing chest X-ray backlogs with limited radiology staff, Qure.ai offers a pragmatic, grant-friendly option. For US-based CMIOs evaluating lung nodule detection or emergency head CT prioritization, the lack of transparent pricing, unclear FDA clearance pathways, and minimal clinician discussion in US forums should trigger caution. This is not a plug-and-play Epic or Cerner integration; expect custom API work and vendor-managed deployment.

Price band is opaque: enterprise contracts are negotiated per study volume, often structured around grant funding or public-health partnerships. Expect costs to be hidden until you engage sales, and budget for implementation services separately. Best fit: international health systems, academic centers with TB research programs, or radiologists in understaffed settings willing to experiment with AI triage. Poor fit: US private practices expecting turnkey PACS integration and predictable per-seat pricing.

Why we picked it

Qure.ai stands out not for technical novelty but for pragmatic global deployment at scale. The company has shipped AI into contexts where traditional vendor solutions never reach: rural Indian hospitals, African TB clinics, Southeast Asian public health programs. This operational track record matters. Many radiology AI vendors demo well but collapse when asked to support low-bandwidth networks, intermittent power, or technicians without radiology training. Qure.ai has solved those problems because its core market demanded it.

The tuberculosis screening application is particularly notable. TB remains a massive global burden, with 10.8 million new cases in 2023, and sputum-based testing is slow and resource-intensive. Chest X-ray screening, augmented by AI to flag high-probability cases, offers a scalable alternative. Qure.ai's qXR product has been integrated into national TB programs and validated in systematic reviews, giving it credibility that pure-research projects lack. For institutions running TB screening workflows, this is a tool with real-world operational mileage, not just a pilot study.

The lung cancer triage angle is newer and less proven, but the logic is sound: chest X-rays are cheap and ubiquitous, but radiologist time is not. An AI that can prioritize worklists, flagging studies with suspicious nodules or infiltrates for urgent human review, could reduce time-to-diagnosis in under-resourced settings. The RADICAL study in BMJ Open 2024 showed clinical effectiveness in a UK context, suggesting the tool can function in developed-world radiology workflows, not just low-resource settings. That cross-context adaptability is rare.

We included Qure.ai because it represents a category of AI tools built for global health challenges first and US commercial markets second. That inverted priority structure produces different tradeoffs: less polish in the user interface, less marketing in US medical conferences, but more operational resilience and lower infrastructure assumptions. For the right buyer, those tradeoffs are advantageous.

What it does well

Qure.ai excels at triage workflows where speed and prioritization matter more than diagnostic certainty. The qXR chest X-ray tool generates abnormality scores in seconds, flagging studies with suspected TB, lung nodules, pleural effusions, or consolidations. Radiologists report that the software reduces the cognitive load of scanning through hundreds of normal films to find the handful that require urgent attention. In settings with weeks-long radiology backlogs, that triage function alone justifies deployment.

The tuberculosis detection specifically benefits from years of training on diverse global datasets. Unlike many AI tools trained primarily on US or European populations, Qure.ai's models have seen chest X-rays from patients in India, Africa, and Southeast Asia, where TB prevalence is high and image quality varies. This training diversity translates to better performance in the exact settings where TB screening matters most. A 2025 systematic review in the Journal of Thoracic Diseases found AI-enabled chest X-ray tools, including Qure.ai, improved sensitivity and specificity for TB detection compared to unaided interpretation, particularly in high-burden regions.

The head CT tool, qER, is less widely discussed but addresses a real pain point: emergency department radiologists triaging trauma and stroke cases under time pressure. The software flags intracranial hemorrhages, mass effects, and midline shifts, allowing ED physicians to escalate critical cases before a radiologist formally reads the scan. In hospitals without 24/7 radiology coverage, this can shave hours off time-to-neurosurgical consultation. The clinical evidence here is thinner than for qXR, but the use case is defensible.

Deployment infrastructure is surprisingly flexible. Qure.ai supports cloud-based API integrations, on-premises installations for data sovereignty concerns, and hybrid models. The vendor has worked with PACS systems from Agfa, Carestream, and Philips, though integration depth varies. For institutions worried about sending PHI to third-party servers, the on-premises option is a meaningful advantage over pure-cloud competitors.

Where it falls short

Pricing opacity is the most immediate barrier for US buyers. Qure.ai does not publish per-study costs, per-seat licensing, or tiered pricing on its website. Sales conversations are required to get even ballpark numbers, and contracts are negotiated individually based on study volume, geography, and whether grant funding is involved. This is standard practice for enterprise medical software, but it creates friction for smaller health systems or solo radiology groups trying to budget. Competitors like Aidoc and Annalise.ai offer more transparent tiering, making them easier to evaluate financially.

US clinical adoption is minimal, at least based on publicly visible signals. Zero mentions in Reddit's physician communities (r/medicine, r/radiology) over the past several years suggests either very low US market penetration or a product that is not generating strong clinician advocacy. In contrast, US-based competitors like Aidoc and RapidAI generate frequent clinician discussion. This absence of organic clinician conversation is a yellow flag: it suggests the tool has not yet proven itself indispensable in US workflows, or that users are not enthusiastic enough to recommend it unprompted.

FDA clearance status is unclear from publicly available documentation. The vendor markets qXR and qER internationally with CE marking in Europe, but explicit FDA 510(k) clearance numbers are not prominently listed on the Qure.ai website as of mid-2026. A 2024 Cureus article mentions FDA-approved tools from Qure.ai, but Cureus is not a high-rigor journal, and the claim lacks specificity. US buyers should demand explicit FDA clearance documentation before procurement. Without it, deployment in US clinical settings may face legal and compliance barriers.

EHR integration depth is shallow for major US systems. Qure.ai can push results into Epic, Cerner, or Meditech via HL7 or FHIR, but this is typically a one-way write of a PDF report or a structured finding note. Bi-directional integration, where the AI pulls patient context from the EHR (prior imaging, clinical history) and feeds risk scores back into clinical decision-support workflows, is not standard. Expect to treat Qure.ai as a standalone radiology module rather than a deeply embedded EHR feature. This increases training overhead and reduces clinician adoption, since results do not surface automatically in the workflows they already use.

Deployment realities

Deploying Qure.ai in a US hospital requires more IT lift than marketing materials suggest. Integration begins with PACS connectivity, either via DICOM routing or a HL7 interface engine. Most implementations involve a Qure.ai technical team working alongside hospital IT for 4 to 12 weeks, depending on PACS complexity and whether the hospital opts for on-premises servers or cloud routing. Hospitals with older PACS systems (GE Centricity, legacy Agfa) report longer timelines due to limited API documentation from PACS vendors, not Qure.ai itself.

Radiologist training is minimal: the tool outputs a visual heatmap overlay and a structured report listing detected abnormalities with confidence scores. Radiologists familiar with any AI decision-support tool can interpret Qure.ai results in under an hour of orientation. The larger training challenge is workflow redesign. If the hospital wants AI-flagged studies to jump to the front of the worklist, that requires PACS worklist customization and consensus among radiologists about prioritization rules. Without that organizational change, the AI results sit in a separate viewer, and radiologists ignore them.

Change management is the hidden deployment cost. Emergency physicians or primary care doctors ordering chest X-rays need to understand that an AI-flagged abnormality is not a diagnosis, just a triage signal. If clinicians misinterpret AI flags as definitive reads and skip radiologist review, patient safety suffers. Conversely, if clinicians distrust the AI and ignore all flags, the tool adds cost without value. Successful deployments involve clinical champions (usually a radiology department chair or CMIO) who communicate the tool's role clearly and audit usage in the first 90 days to ensure appropriate uptake. Budget 20 to 40 hours of clinical leadership time for this, separate from IT implementation.

Pricing realities

Qure.ai operates on an enterprise per-study model, meaning costs scale with imaging volume rather than user seats. Published pricing is zero, listed only as 'Enterprise' with the note that contracts are often grant-funded. This suggests the company targets government health programs, academic research centers, and international NGOs more than US private-practice radiology groups. For a mid-sized US hospital processing 50,000 chest X-rays annually, expect a negotiated per-study fee in the range of $1 to $5 per image, but this is speculative absent public benchmarks.

Hidden costs emerge in three areas. First, implementation services: Qure.ai typically bundles technical integration and initial training into the contract, but customization beyond standard PACS connectivity (e.g., worklist automation, multi-site deployments, hybrid cloud-on-prem splits) may incur additional professional services fees. Second, ongoing support: annual maintenance contracts cover software updates and technical support, but premium SLAs (e.g., 24/7 phone support, dedicated account manager) cost extra. Third, data egress fees: if the hospital uses cloud routing and later wants to migrate to on-premises, extracting historical AI annotations from Qure.ai's cloud may incur data transfer costs.

ROI math is favorable in high-volume, low-radiologist-staffing scenarios. If a hospital has a 3-week backlog for non-urgent chest X-rays and one radiologist reading 100 films per day, an AI that prioritizes the 10 percent of studies with actionable findings could reduce time-to-critical-diagnosis by days. That time savings is clinically meaningful for lung cancer and TB cases. However, in a well-staffed US academic center with same-day turnaround already achieved, the marginal value is smaller, and the tool becomes harder to justify financially. The strongest ROI case is international public health programs where radiologist scarcity is extreme and even modest triage gains prevent hundreds of missed diagnoses annually.

Compliance + integration depth

HIPAA compliance is claimed but not transparently documented. Qure.ai's website states HIPAA-compliant infrastructure for US customers, but a publicly available BAA (Business Associate Agreement) template or SOC 2 Type II report is not linked. US buyers should request these documents during procurement. For on-premises deployments, where PHI never leaves the hospital network, HIPAA risk is minimal. For cloud-based routing, where images transit to Qure.ai's servers for analysis, hospitals must verify encryption in transit and at rest, data retention policies, and geographic storage locations (whether US-domiciled servers are guaranteed).

SOC 2 and HITRUST certifications are not advertised on the vendor website as of mid-2026. This is unusual for a medical AI vendor selling into US healthcare systems, where these certifications are increasingly table stakes. Competitors like Aidoc prominently display SOC 2 Type II and HITRUST badges. The absence here suggests either that Qure.ai has not pursued these certifications (because its primary market is international, where they matter less) or that certifications are in progress. Either way, US compliance officers will flag this gap.

EHR integration depth is basic. Qure.ai connects to Epic, Cerner, Meditech, and Allscripts via HL7 or FHIR to deliver structured findings and PDF reports. This is a one-way push: the AI does not pull patient history, prior imaging, or clinical notes from the EHR to contextualize its analysis. As a result, the AI treats each image in isolation, which is clinically suboptimal (e.g., a nodule flagged today might be stable compared to a prior X-ray from six months ago, but the AI cannot know that without EHR integration). Radiologists must cross-reference manually. Deeper integration, where the AI queries the EHR for priors and adjusts its output accordingly, is technically feasible but not standard and would require custom development work.

Vendor stability + roadmap

Qure.ai is venture-backed with multiple funding rounds since its 2016 founding, including investments from Sequoia India, MassMutual Ventures, and others. The company has not disclosed total funding amounts publicly, but its operational scale (90-plus countries, partnerships with national TB programs, multi-year deployments in the UK NHS) suggests stable revenue and runway. There are no public reports of layoffs, leadership churn, or acquisition rumors as of mid-2026, which is reassuring for buyers worried about vendor continuity.

Customer references include the UK's National Health Service (via the RADICAL study), the Indian Council of Medical Research, and TB screening programs in sub-Saharan Africa. These are credible, high-stakes deployments that suggest the vendor can support large, multi-site implementations. However, named US health system customers are not prominently featured in case studies or press releases, reinforcing the impression that US market penetration is limited. Buyers should ask for US-based references during evaluation.

The product roadmap, based on vendor communications and recent publications, emphasizes expanding qXR beyond TB and lung nodules into broader cardiothoracic pathology (cardiomegaly, pneumothorax, rib fractures) and enhancing qER for a wider range of intracranial findings. A 2026 case series in Cureus suggests the vendor is positioning qXR as an incidental lung cancer detection tool, not just a TB screener, which would align with US clinical needs where TB prevalence is low but lung cancer is a top concern. This pivot, if sustained, could improve US market fit. However, public roadmap details are sparse, and buyers should press the vendor for commitment timelines on specific features during contract negotiations.

How it compares

Against Aidoc, a US-based radiology AI leader, Qure.ai is less polished but more globally adaptable. Aidoc offers FDA-cleared modules for pulmonary embolism, intracranial hemorrhage, and C-spine fractures, with deep Epic integration and a predictable per-site licensing model. US hospitals with existing Aidoc deployments will find it easier to add more Aidoc modules than to onboard Qure.ai. However, Aidoc's strength is US acute care, not TB screening or resource-constrained settings. For international deployments or TB-specific workflows, Qure.ai is the better fit. Price-wise, Aidoc is likely more expensive for equivalent imaging volumes, though neither vendor publishes transparent pricing.

Versus Annalise.ai, an Australian competitor with FDA-cleared chest X-ray AI, Qure.ai has stronger TB credentials but weaker US clinical validation. Annalise.ai's CXR tool is cleared for detection of 124 findings and integrates with major PACS vendors. It also publishes transparent tiered pricing (per-study and per-seat models), making it easier to budget. Annalise.ai has more visible US radiology community engagement and clearer FDA pathways. For US buyers prioritizing regulatory clarity and pricing transparency, Annalise.ai wins. For global health buyers or academic TB researchers, Qure.ai's disease-specific training and deployment track record are more relevant.

Compared to Lunit INSIGHT CXR, another global chest X-ray AI with strong Asian market presence, Qure.ai is operationally similar but with deeper TB focus. Lunit emphasizes lung nodule detection for cancer screening and has CE and FDA clearances. Both vendors target international markets first, both offer on-premises deployment for data sovereignty, and both lack US clinician buzz. The choice between them hinges on specific use case: Lunit for lung cancer screening programs, Qure.ai for TB triage. Pricing is opaque for both, so expect similar negotiation processes.

Against purely US-focused competitors like Riverain ClearRead or RapidAI's CXR module, Qure.ai is at a disadvantage in the US market due to weaker sales presence, less transparent pricing, and minimal US clinical champion network. These US vendors integrate more smoothly with US radiology workflows and have stronger track records with US payers and compliance officers. However, their global footprint is smaller, making them poor choices for international health systems. The comparison highlights that Qure.ai is optimized for a different buyer: the one prioritizing global scalability, grant-fundability, and low-resource adaptability over US-market polish.

What clinicians say

Clinician discussion in US online forums is absent. Searches across Reddit's medical communities (r/medicine, r/radiology, r/Residency) over the past several years return zero mentions of Qure.ai in clinical practice discussions. This is notable given that competing radiology AI tools like Aidoc, RapidAI, and Zebra Medical generate regular organic clinician commentary. The absence could reflect low US adoption, limited marketing to US clinicians, or a product that has not yet generated strong advocacy among early users.

Published clinician perspectives from the RADICAL study in BMJ Open 2024 offer some insight. The study evaluated qXR in UK primary care and radiology settings for lung cancer detection. Clinicians interviewed in the mixed-methods portion reported that the AI increased confidence in prioritizing abnormal chest X-rays but also noted concerns about over-reliance and the risk that non-radiologist users might misinterpret AI flags as definitive diagnoses. Radiologists appreciated the triage function in high-volume settings but emphasized that the AI did not replace clinical judgment, only augmented worklist prioritization. These are measured, pragmatic reactions, not enthusiastic endorsements.

Anecdotal evidence from academic radiology conferences (RSNA, ECR) suggests that Qure.ai is better known among international radiologists and global health researchers than among US private-practice radiologists. The vendor's presence at TB-focused conferences and global health forums is stronger than at US commercial radiology events. This aligns with the zero-Reddit-mentions data point: the tool is not yet embedded in US clinical workflows deeply enough to generate grassroots clinician conversation. For US buyers, this should be a caution flag, not a dealbreaker, but it means there is less peer validation available when pitching the tool to your radiology department.

What the literature says

The evidence base is thin but present, with five PubMed-indexed studies as of mid-2026. The strongest is the RADICAL trial published in BMJ Open 2024, a mixed-methods study assessing qXR's clinical effectiveness and acceptability for prioritizing chest X-ray interpretation in UK settings. The study found that qXR successfully flagged suspicious cases and was clinically acceptable to radiologists, though it stopped short of demonstrating a reduction in time-to-cancer-diagnosis or survival benefit. This is a pragmatic, real-world validation study, not a definitive outcomes trial, but it is the kind of evidence that should satisfy US procurement committees looking for peer-reviewed support.

A 2025 systematic review and meta-analysis in the Journal of Thoracic Diseases evaluated AI tools for TB diagnosis via chest X-ray, including Qure.ai's qXR. The review found that AI-enabled interpretation improved sensitivity and specificity compared to unaided human interpretation, particularly in high-burden settings where TB prevalence is high and radiologist expertise is limited. This supports Qure.ai's core use case: TB triage in resource-constrained regions. However, the meta-analysis pooled multiple AI tools, so the specific performance gains attributable to Qure.ai alone are less clear.

Two articles in Cureus (2024 and 2026) discuss Qure.ai, but Cureus is a lower-tier open-access journal with less rigorous peer review than BMJ Open or specialty society journals. The 2024 Cureus article is a broad overview of Qure.ai's product suite, more marketing summary than original research. The 2026 case series on incidental lung cancer detection is more substantive, describing how qXR flagged early-stage cancers in asymptomatic patients undergoing chest X-rays for other reasons. However, case series are low-level evidence, and the study's small sample size limits generalizability. A 2026 study in the Journal of Infectious Diseases evaluated TB severity assessment using Qure.ai alongside clinical variables, finding that radiological AI metrics predicted treatment outcomes better than clinical variables alone. This is hypothesis-generating work, not practice-changing, but it adds to the evidence that AI radiology tools can provide clinically useful information beyond binary presence-absence calls. Taken together, the literature suggests Qure.ai is a credible tool with real-world validation in TB screening and emerging evidence in lung cancer triage, but the evidence is not yet deep enough to support widespread US deployment without additional trials.

Who it's for

Qure.ai is best suited for three buyer profiles. First, international health systems and NGOs running TB screening programs in high-burden countries (India, sub-Saharan Africa, Southeast Asia). If your institution processes thousands of chest X-rays annually for TB case-finding and faces severe radiologist shortages, Qure.ai offers a proven, grant-friendly solution with operational track record. This is the tool's core market, and it excels here. Second, academic medical centers in the US or Europe with global health research programs or TB clinics serving immigrant populations. If you are running TB research trials or serving patient populations with high TB prevalence, Qure.ai's disease-specific training gives it an edge over general-purpose chest X-ray AI. Third, radiology groups in underserved US regions (rural hospitals, safety-net systems) with chronic staffing shortages and multi-week backlogs for non-urgent imaging. If triage speed is your bottleneck and you are willing to tolerate opaque pricing and custom integration work, Qure.ai can help.

Who should hesitate: US private-practice radiology groups or well-staffed academic centers looking for plug-and-play PACS integration. The lack of transparent pricing, shallow EHR integration, and minimal US clinical champion network make evaluation harder. If you need a tool that your radiologists can test-drive via peer recommendations and that your CFO can budget without a multi-month sales cycle, look at Aidoc or Annalise.ai first. Qure.ai may still be competitive on price after negotiation, but you will spend more time in the evaluation phase.

Who should skip it: Small US hospitals or solo practices with low imaging volumes (fewer than 10,000 chest X-rays per year) or those expecting turnkey Epic integration and predictable per-seat licensing. Qure.ai's enterprise-only sales model and custom integration requirements make it a poor fit for small buyers. Similarly, hospitals that need AI for pulmonary embolism, aortic dissection, or pneumothorax detection should look elsewhere; Qure.ai's chest X-ray tool is focused on TB, lung nodules, and infiltrates, not the acute cardiothoracic emergencies that drive ED radiology workflows in the US. Finally, if your procurement process requires FDA 510(k) clearance as a hard gate, confirm clearance status with Qure.ai before proceeding, as public documentation is unclear.

The verdict

Qure.ai is a pragmatic, operationally proven AI radiology tool optimized for global health settings and TB triage workflows. Its strengths are deployment flexibility, diverse training datasets, and real-world operational mileage in resource-constrained environments. Its weaknesses are pricing opacity, limited US clinical adoption, shallow EHR integration, and an evidence base that, while growing, remains thinner than US-market leaders. For the right buyer, those tradeoffs are acceptable. For others, they are dealbreakers.

Decision rules: If you are running a TB screening program in a high-burden region, or if you are an academic center with TB research mandates, Qure.ai is a strong pick. If you are a US CMIO at a well-staffed hospital evaluating lung nodule detection AI, start with Aidoc or Annalise.ai and return to Qure.ai only if pricing or specific feature gaps push you to consider alternatives. If you are a solo radiology practice or small community hospital, skip Qure.ai entirely; the enterprise sales model and integration complexity are not built for you. If you are grant-funded or working with international NGOs, Qure.ai's willingness to structure contracts around grant timelines is a unique advantage that competitors may not match.

The tool is not revolutionary, but it is competent and operationally resilient. It will not transform your radiology department, but it can reduce backlogs and prioritize urgent cases in settings where radiologist time is the constraining resource. The evidence supports cautious adoption for TB screening and exploratory use for lung cancer triage, but widespread deployment in US acute care settings should wait for deeper US validation studies and clearer FDA regulatory positioning. For international health buyers, the verdict is more favorable: this is a tool that works where others do not, and that operational adaptability is worth the tradeoff in polish.